Who owns Nektar Therapeutics?
- CUSIP Number: 640268108
Tip: Access positions for across all investors
Analyze quarterly positions in Nektar Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Nektar Therapeutics stock
Who bought or sold Nektar Therapeutics this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| 49 Wealth Management | 6.0k | $340k | 100% | Sep 2025 |
|
| Parallel Advisors | 1.1k | $60k | 0% | Sep 2025 |
|
| EverSource Wealth Advisors | 110.00 | $6.3k | -86% | Sep 2025 |
|
| Rise Advisors | 69.00 | $3.9k | 41% | Sep 2025 |
|
| Fortitude Family Office | 21.00 | $1.2k | 100% | Sep 2025 |
|
| AllSquare Wealth Management | 18.00 | $464.999400 | -94% | Jun 2025 |
|
| Nova Wealth Management | 16.00 | $910.000000 | 60% | Sep 2025 |
|
| Huntington National Bank | 1.00 | $1.000000 | 0% | Sep 2025 |
|
| LRI Investments | 1.00 | $57.000000 | 0% | Sep 2025 |
|
Who sold out of Nektar Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Goldman Sachs Group | Mar 2025 | 531k | $361k |
| Jpmorgan Chase & Co | Mar 2025 | 491k | $334k |
| Cibc World Markets | Mar 2025 | 40k | $27k |
| IFP Advisors | Jun 2025 | 4.5k | $3.0k |
| Atlas Capital Advisors | Mar 2025 | 600.00 | $408.000000 |